课题基金 / 基金详情

Phosphodiesterases 3 and 4 regulate local Ca2+ releases and beating of pacemaker

Phosphodiesterases 3 and 4 regulate local Ca2+ releases and beating of pacemaker
磷酸二酯酶 3 和 4 调节局部 Ca2 释放和起搏器跳动
批准号:
7963906
负责人:
Edward Lakatta
金额:
$9.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

Edward Lakatta的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Spontaneous beating of rabbit SANC is controlled by cAMP-mediated, PKA-dependent rhythmic, local subsarcolemmal Ca2+releases (LCRs) from sarcoplasmic reticulum during late diastolic depolarization. While Ca2+influx via L-type Ca2+ channels ensures LCR occurrence, high basal PDE activity limits LCRs. The extent to which PDE regulates L-type Ca2+ current, ICa,L, however, remains enigma. We determined the extent of PDE subtype-dependent control of basal ICa,L, spontaneous SANC firing rate; and compared those to the effect of -adrenergic receptor (-AR) agonist, isoproterenol. A specific PDE4 inhibitor, rolipram, had no effect, on either ICa,L or spontaneous beating; cilostamide, a specific PDE3 inhibitor, in contrast, increased both ICa,L and spontaneous SANC firing. Simultaneous inhibition of PDE3 and PDE4 by (cilostamide+ rolipram) increased ICa,L; amplified LCR size (from 5.90.58 to 8.60.50 m); decreased the LCR period (from 309.720.6 to 214.33.9 msec); and accelerated spontaneous SANC firing rate equivalent to broad-spectrum PDE inhibitor, IBMX. These effects were even greater than those produced by -AR stimulation. Thus, concerted PDE3 and PDE4 activities control basal cAMP-PKA-dependent phosphorylation and suppress ICa,L, limiting basal LCRs and spontaneous SANC firing rate.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A PUFA Dietary Intervention for Heart Rate
  • 批准号:
    8335786
  • 项目类别:
  • 资助金额:
    $25.83万
  • 财政年份:
    --
  • 负责人:
    Edward Lakatta
  • 依托单位:
Decreased pacemaker activity in aged sinoatrial node
  • 批准号:
    8335801
  • 项目类别:
  • 资助金额:
    $11.03万
  • 财政年份:
    --
  • 负责人:
    Edward Lakatta
  • 依托单位:
Soluble Receptor for Advanced Glycation End Products for Therapeutic Application
  • 批准号:
    8552494
  • 项目类别:
  • 资助金额:
    $12.3万
  • 财政年份:
    --
  • 负责人:
    Edward Lakatta
  • 依托单位:
Therapeutic Potential of EPO and its Derivatives for Reducing Blood Pressure
  • 批准号:
    9147229
  • 项目类别:
  • 资助金额:
    $15.43万
  • 财政年份:
    --
  • 负责人:
    Edward Lakatta
  • 依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    乔安娜
  • 依托单位: